In diabetes treatment, DPP4 inhibitors have been a vital focus, but now, there’s a fresh perspective on microbial DPP4. Let’s explore this emerging concept, its implications, and potential advancements in type 2 diabetes management.
INCRETIN-BASED THERAPIES
While the anti-diabetic therapies majorly include insulin secretagogues and insulin sensitizers, important advancements have occurred in the last few years in the field of diabetes treatment. The priority in the therapy of patients with diabetes is not only glycemic control per se but it now includes an overall management of risk factors with individualization of glycemic target.
The drugs which are used as second line agents (after metformin) in the therapeutic algorithm of type 2 diabetes mostly represented by the incretin-based therapies. This includes glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors.
DPP4 INHIBITOR ADVANTAGE
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
KIMSHEALTH launches electrophysiology lab with 3D mapping
'ENSITE X' is the first of its kind in Kerala and the third in India enabling precise identification, mapping, and targeting the abnormal electrical activities in the heart.
Molbio boosts Goa's healthcare system with CSR initiatives
The company has donated four state-of-the-art Advanced Life Support (ALS) ambulances and two hearse vans for National Highway emergencies
USV introduces affordable heart failure medication
This cost-effective option addresses the rising cases of heart failure in India, offering lifesaving care to millions of patients who need it the most.
City Imaging & Clinical Labs to expand services to 50 hospitals
The company is currently associated with 10 hospitals, providing comprehensive lab management services, including 24/7 in-house phlebotomy and lab testing.
Oncare raises $1 million in seed funding, to set up 10 units
Oncare has raised $1 million in a seed funding round led by Huddle Ventures. It plans to deploy the raised capital to expand its operations to 10 new centers.
Nutrabay forays into Ayurvedic supplements market with Shilajit
Nutrabay's aims at gaining market share from the existing ayurveda supplements market with a distinctive product proposition and education about the benefits of Shilajit.
INDIA'S PREPAREDNESS ON HEALTHCARE-ASSOCIATED INFECTIONS: A GROWING FOCUS ON PATIENT SAFETY
The country's diverse healthcare landscape necessitates a flexible and multifaceted approach to infection control that can be adapted to various settings and resource levels.
TRANSFORMING CARDIAC SURGERY: HOW AI IS REVOLUTIONIZING PATIENT CARE AND OUTCOMES
Dr. Swarup Swaraj Pal shared his insights on the current state and future prospects of AI in cardiac procedures.
BEYOND THE LAB: THE CRITICAL ROLE OF LOGISTICS IN INDIA'S PHARMACEUTICAL INDUSTRY
As India continues to expand its role in the global pharmaceutical market, the importance of a robust, reliable, and innovative logistics infrastructure cannot be overstated.
LIFESTYLE DISEASES IN CHILDREN: A WAKE-UP CALL FOR A HEALTHIER GENERATION
In today's fast-paced world, children face an unexpected enemy: lifestyle diseases. Conditions like obesity, Type 2 diabetes, and hypertension are now affecting our youth. What's causing this shift, and how can we combat it?
